Citations 1
Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)
Carter, Lawrence , Mummery, Catherine J. , Ber, Isabelle Le, Boeve, Bradley, Boxer, Adam L. , Chow, Tiffany W. , Huang, Julie , Salvadore, Giacomo , Romano, Gary, Borroni, Barbara , Ber, Isabelle Le , Smithey, Megan J. , Guizzetti, Leonardo
Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available
